Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aprea Therapeutics Q2 EPS $(0.53) Beats $(0.74) Estimate, Sales $118.111K Down From $561.574K YoY

Author: Benzinga Newsdesk | August 12, 2025 07:11am
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.74) by 28.86 percent. This is a 8.62 percent increase over losses of $(0.58) per share from the same period last year. The company reported $118.111 thousand in sales this quarter. This is a 78.97 percent decrease over sales of $561.574 thousand the same period last year.

Posted In: APRE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist